Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRHYTHM TECHNOLOGIES, INC.

(IRTC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

iRhythm Technologies : Morgan Stanley Adjusts Price Target on IRhythm Technologies to $85 From $94, Keeps Equal-Weight Rating

06/03/2021 | 11:14am EDT


© MT Newswires 2021
All news about IRHYTHM TECHNOLOGIES, INC.
07/29IRHYTHM TECHNOLOGIES : ® Technologies to Present at the 41st Annual Canaccord Ge..
AQ
07/22IRHYTHM TECHNOLOGIES : to Report Second Quarter 2021 Financial Results on August..
AQ
07/14iRhythm® Technologies Comments on the Centers for Medicare and Medicaid Servi..
GL
07/08iRhythm® Technologies and the National Association of Managed Care Physicians..
GL
07/08IRhythm Technologies and the National Association of Managed Care Physicians ..
CI
07/06IRHYTHM TECHNOLOGIES, INC. : Change in Directors or Principal Officers (form 8-K..
AQ
06/25IRHYTHM TECHNOLOGIES, INC.(NASDAQGS : IRTC) dropped from Russell 2000 Growth-Def..
CI
06/25IRHYTHM TECHNOLOGIES, INC.(NASDAQGS : IRTC) dropped from Russell 2000 Defensive ..
CI
06/21IRHYTHM TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders..
AQ
06/03IRHYTHM TECHNOLOGIES : Morgan Stanley Adjusts Price Target on IRhythm Technologi..
MT
More news
Financials (USD)
Sales 2021 303 M - -
Net income 2021 -102 M - -
Net cash 2021 68,0 M - -
P/E ratio 2021 -14,9x
Yield 2021 -
Capitalization 1 498 M 1 498 M -
EV / Sales 2021 4,72x
EV / Sales 2022 4,41x
Nbr of Employees 1 157
Free-Float 98,7%
Chart IRHYTHM TECHNOLOGIES, INC.
Duration : Period :
iRhythm Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRHYTHM TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 51,12 $
Average target price 89,80 $
Spread / Average Target 75,7%
EPS Revisions
Managers and Directors
Douglas J. Devine Chief Executive & Financial Officer
Abhijit Y. Talwalkar Chairman
Judith Lenane Chief Clinical Officer & Executive VP-Products
Mark J. Day Executive Vice President-Research & Development
Allan B. Wilsker EVP-Information Technology & Customer Services
Sector and Competitors